Commercial/Advertisement Announcer (11:16)

Now known as the pioneer of Paso Justin vineyards and winery produces exceptional wines perfect for enjoying this holiday season. Like Isosceles, their flagship Bordeaux style red blend. Justin Wines also offers unique and thoughtful gifts. Pick your wine, choose a box and add a personal message, icon or logo. You'll also find curated gift sets, library wines, magnums, even custom etched bottles. Start gifting today. Visit justinwine.com and use promo code money20 to receive 20% off your order for a limited time Hiring isn't just about finding someone willing to take the job. Count on Indeed sponsored Jobs to find the right person with the right background who can move the business forward. Stop struggling to get your job post even seen on other sites. Give your job the best chance to be seen with Indeed's sponsored jobs. They boost your post for quality candidates so you can reach the exact people you want faster and it makes a big difference. According to Indeed data, sponsored jobs posted directly on Indeed are 90% more likely to report higher than non sponsored jobs. Plus, with Indeed sponsored jobs, you only pay for results. No monthly subscriptions, no long term contracts. Just a boost whenever you need to find quality talent Fast. Join the 1.6 million companies that sponsor their jobs with Indeed. Get a $75 sponsored job credit to help get your job the premium status it deserves@ Indeed.com MadMoney.

Jim Cramer (12:53)

Even though stocks came roaring back today thanks to some dovish comments from the president of the New York Fed, well, it was still a pretty rocky week for stocks, and when times get tough, you always have the option of camping out in the relative safety of high quality dividend stocks. Now these days, as I write in how to Make Money in Any Market, growth is your best defense in any environment. But I'll never fault anyone for wanting some dividend protection, especially when the market's looking shaky and short term interest rates might become down. So tonight I want to highlight not one, not two, but three excellent companies with yields north of 5% that have been brought down by some of the sell off. I want to start with one that has long been my favorite called Enbridge is Canadian pipeline company with a sprawling network of pipes for crude oil and natural gas across North America, along with storage infrastructure, natural gas, utilities, even some renewable energy assets. Enbridge Transports Amazing about 30. No one knows these guys, but they transport 30% of the crude oil produced in North America along with nearly 20% of the natural gases consumed the United States. Best of all, the stock sports a dividend yield of just over 5.6%. Now you haven't had me. I'm not talking much about these energy stocks, but I don't know if you notice that, but that's because we have A drill, baby drill White House. And that generally leads to lower oil and gas prices. Although NAT gas has spiked recently after spending most of the year trending lower. But oil is clearly coming down. That said, Enbridge is not like the producers. The pipeline operators are basically toll roads for energy. They're much less levered to the price of the underlying commodities and more levered to volumes. So if we produce more oil, which we are doing, that is great for Enbridge and its compadres. Plus, this is incredibly predictable business with a deep pocketing customer base. The only real worry for pipeline operators is government regulation. But with Trump in the White House, there's not something we need to care all about, is it? There's a reason Enbridge has given you a total return of almost 20% year to date. Given the nearly 6% yield and the resilient business model, I think this one gives you a ton of downside protection. At the same time though, Enbridge also has a terrific long term growth story. Our country is desperate to produce more electricity to fuel the data center boom. And when you hear a lot about new nuclear plants, well, those can take over a decade to build. Natural gas plants, on the other hand, go up much faster. And look, we're sitting on almost endless amounts of NAT gas here in America. Doesn't hurt that we have all these natural gas export terminals being built. They all need pipeline access to. Plus, I had Enbridge in my mind this week after the company is flagged in a great article by RBN Energy. That's Rusty Brazil's firm. He's our go to source for the entire industry. RBM put up this fantastic piece highlighting how Enbridge is in the early stages of a major pipeline expansion effort which will help transport more crude oil from Canada and the Midwest down to the Gulf of Mexico. Sounds good to me. As does the entire Enbridge story, frankly. Which makes this one of my top choices for anyone who wants some yield. When you put up more pipe, you can get a better distribution. And distribution's eye anyway. All right, next up, controversial. It's Pfizer. It's the big pharma titan. 6.9% yield. Now I got to tell you, these days I see Pfizer is basically a bond equivalent. The days of the COVID year dominance, they're long gone. While the stock finally found a bottom in the low 20s earlier this year, it's been pretty much stuck in the mid-20s for months. In other words, it hasn't given you much in the way of share price appreciation. Hence its controversial Nature. But since it yields nearly 7%, you can still get a decent return. Even stock does nothing. Although I obviously want to do something. Still, if you're worried about volatility and maybe another big sell off in the market, is a bond market equivalent really that bad? At the same time, I think the Pfizer has the ability to use some of the businesses it's acquired in recent years to build up a powerful pipeline. One that's bountiful enough to offset the wave of the of patent expirations that everybody seems to be so worried about. When it comes to Pfizer. Pfizer uses Covid cash requires that's a cancer specialist. And Nerdtech, which is a revolutionary migraine treatment that they picked up from Biohaven Pharmaceuticals. Most recently the company paid about $7 billion plus some milestone payment down to the Dubai this company called Met Sara and that's working on one of these GOP Dash one weight loss drugs that market so used that there's plenty of room for many different drugs. Even as we know that Lilly is the the dominant company. Of course pulling all this off, it's going to be a toll order. Many are betting that Pfizer can't do it, which is why the stock sells for less than 8, 8 times earnings in that near 7% yield. But I think they can easily cover the dividend with their $15 billion in free cash flow and long term, Pfizer has enough shots on gold that it can get through this tricky period and come out the other side as growth business. As it gets more growth. Now, it's controversial only because it's done nothing I think and I think it can be near a breakout. Finally, we've got a real estate investment trust, Realty Income, letter o. With its 5.7% yield, these guys own a portfolio of roughly 15,500 commercial properties that are mostly leased to retail or industrial clients. Of course, Realty Income is best known for paying its dividend monthly rather than quarterly. By the way, they've also raised that dividend four separate times this year alone. Now, the stock hasn't exactly been on fire. Lates up just over 6% for the year, though the total return is closer to 12%, not far behind the S&P 500. Realty Income pulled back after its latest quarter in part because the company managed a slight beat for the period, but merely tightened its full year outlook rather than raising it. There's also some concern about a few of their tenants like Walgreens, which plans to close a ton of stores over the next few years. Look, Wall street started worrying about credit, corporate credit. Last month. Some investors just dumped Realty Income because they were worried about it. Tenant base. You know what? I'm more sanguine. First Realty Income's occupancy rates stood at 98.7% at the end of the third quarter. And the company had a rent recapture rate of 103.5% across almost 300 leases signed in the quarter. This is clearly not a landlord struggling to find paying tenants. Plus, most of their tenants are grocery stores or convenience stores or dollar stores or home improvement stores. All right, you can quibble about the home improvement business. Home depot was up $10. Say that. But the other three groups sell necessities. They'll do just fine, even in an economy where many consumers are struggling. And look, no single tenant accounts for more than 3.3% of Realty Income's rent base. So even if they lose a couple, it's not a big deal. Even during the global financial crisis, their annual occupancy rate never dipped below 96.6%. If that's the worst case scenario, I'd say, well, we've got nothing to worry about here. This is a sleep at night stock that pays you a nearly 6% yield in monthly installments. I think the stock's recent pullback is, yes, a buying opportunity. Here's the bottom line if you're looking for some yield protection in this newly volatile market. I like Enbridge, I like Pfizer, and I like Letter O Realty Income. There are a lot of high yielders that are dangerous. Their yields soar because investors don't believe the company can keep covering the cost of dividend. But these, these three are not like it. And I regard them as very, very safe. Their money is back into the bank. Coming up is beauty in the eye of the stockholder. Kramer's digging into cosmetics player oddity. See if now's the time to get into the company after days of big gains. Next.

Commercial/Advertisement Announcer (20:05)

Fifth Third Bank's commercial payments are fast and efficient. But they're not just fast and efficient. They're also powered by the latest in payments technology built to evolve with your business. Fifth Third bank has the big bank muscle to handle payments for businesses of any size. But they also have the fintech hustle that got them named one of America's most innovative companies by Fortune magazine. Big bank muscle. Fintech hustle. That's how Fifth Third brings you the best of all worlds. Going above and beyond the expected handling over $17 trillion in payments each year with zero friction. They've been doing it that way for 167 years. But fifth third also never stops looking to the future to take their commercial payments two steps ahead of tomorrow. Constantly evolving to suit the ever changing needs of your business. Big bank muscle fintech hustle. That's your commercial payments. A fifth third better streaming is changing.

Jim Cramer (20:57)

The way we watch live sports and your Internet connection can be the difference between catching the game winning touchdown as it happens or hearing about it from your neighbors. Cheer. That's why Comcast is building the network of the future. Using cutting edge AI and edge computing technology. We're bringing fans closer to the action.

Commercial/Advertisement Announcer (21:14)

In stunning high definition with ultra low latency.

Jim Cramer (21:17)

It's not just fast, it's game changing. Learn more@comcastcorporation.com sports this ad is only 15 seconds. In that amount of time there are likely to be an average of over 15,000 cyber threats to all businesses, so there's no time to wait. Get threat ready with comcast business@comcastbusiness.com, cybersecurity. Earlier this week, a beaten down direct to consumer cosmetic stock Oddity Tech reported a great quarter and the stock shot up 21%. Its highs yesterday for the entire market of course rolled over and gave back those gains only finished up just 6.5% today, got hit for another 4.7%. At this point I think you're almost getting that terrific quarter for free. I think this is one of those babies that got thrown out with the proverbial bathwater and right now it's a compelling buying opportunity. Of course to be fair, I don't have the best track record in the stock. Back in the beginning of May the company reported a fantastic beat and race quarter and caused the stock to soar. I told you not to chase, but that it was buying on a pullback at that the stock kept running and running running for the next few months and it eventually gave back all the gains from its springtime breakout. I was right to say you shouldn't chase it, but even when we got to the pullback, I told you to wait for just kept and it just kept going lower. So you could argue I have not called it right. But now some of that is because of peculiar things that occurred. For instance, the co founder and CEO Oren Holtzman. He sold a huge chunk of stock in May, 5.5 million shares in a block trade worth over 350 million. I didn't see that coming. That didn't set off any red flags at the end. But you never want to see big insiders telling, especially of that size. Then in June, Oddity did this gigantic bond offering raising $525 million. Now, there's nothing inherently wrong with going to the bond market to raise money. However, one of the reasons I initially liked Oddity is that a pristine balance sheet, zero debt, that's no longer the case. And it's what initially knocked the stock off its highs. Then when Audi reported in early August, the Stock immediately fell 22% even though the company posted another beat and raised set of numbers. The stock got hammered because it had run up going into the earnings. There was actually very little that was wrong with it. It's just that investors had come to expect another gargantuan earnings beat. And when we got a smaller beat instead, well, a lot of people just headed for the hills from that post. Earnings sell off in August through Wednesday. Oddity just kept getting blasted. Two days ago it was less than a dollar away from its 52 week low. It felt like Oddity had been written off and left for dead. Even though the company kept putting up great numbers, the stock just couldn't find its footing. But you know what? That will change yesterday when Audi reported on Wednesday night the company delivered a healthy revenue beat 24% year over year to just under $148 million, beating the 145.5 million that Wall street was looking for. Their gross margins is really important. Shot up 170 basis points to 71.6%. Cosmetics, very hard to have that big gross margin and also look for 68.1%. And they posted a 4 cent earnings beat off a 36 cent basis. That's 25% earnings growth year over year. Very strong. What's driving this rate? Okay, Oddities. Original two brands, Ilmaciage and Spoiled Child, both were double digits. Ilmaciage is doing very well with international sales company has launched the brand in more and more foreign markets. Magic believes that oh my gosh. Can reach $1 billion in sales by 2028. Keep in mind Odyssey only this only a $2 billion company. Now we've got less detail and spoil Child. Curious name but management now expects this brand across $225 million in revenue this year. And they sound pretty confident about what they've got lined up for next year. But you know what? The big news here and what really attracted me to it, why I wanted to do this piece is that Oddities launching its third brand. The company actually announced this on Tuesday, the day before the earnings report and it's called Methodic, but it's spelled Method iq. Apparently this is more than just a cosmetics and skin care brand. Methotic is meant to be a medical telehealth platform delivering customized high efficacy skin care treatments after an online diagnosis. No doctors required. With oddities direct to consumer model, you don't need to go to a drugstore either. Management says that Methodics addressing a major unmet need in dermatology. Nearly 50 million Americans have acne, 30 million have eczema and 30 million have hyperpigmentation. If you want to go on, you can either try what I think are somewhat ineffective over the counter medications where you go to the doctor which I regard as a pain in the butt and possibly expensive depending on your insurance. How is Methodic different? According to Oddity, their tech integrates AI powered skin analysis, computer vision based progress tracking and what Management describes as another quote here, high efficacy prescription and non prescription treatments. End quote. On the conference call Wednesday night, CEO Orrin Holtzman said that Methodic was testing and quote unprecedented scale of over 20,000 real user trials. He added that while they're starting dermatology, the long term goal is to expand this technology into all sorts of diseases. Oddity spent a fortune developing his platform, which may be why they needed to raise money earlier this year. I was kind of sympathetic to that. Beyond this new brand, Oddity also raised its full year forecast on Wednesday night with every major line coming in above expectations. Their guidance for the fourth quarter, some thought it was mixed. The revenue outlook was terrific, but their earnings guide came in a tad light. Still, between the strength of the reported quarter, the raised full year forecast and the excitement about this methodic launch stock caught fire instantly. Soaring in after hours trading was up over 25% its highs yesterday the stock opened up nearly 15% and its highs as high as yesterday, although it was up 21%. Eventually though, the broader market reversed and took Oddity down with it. So the stock finished the day up just 6.5% and then today the stock pulled back some more. To me this seems like the real opportunity here this spring. I told you that I really like the outer story, but I told you not to chase it. Right now the story is the same. In fact I'd argue it's much better with a series of beat and raise quarters coupled with this new telehealth brand on the way that really I found very intriguing. And this time you're doing the opposite of chasing, you're buying into weakness. In May I said the stock was expensive. Around 30 times earnings. Well, it's now selling for less than 18 times this year or just 17 times. Really 17 times next year's numbers. I regard that as cheap. In fact, I even go so far as to say that next year's estimates look pretty low to me. Applying just 4% year over year earnings growth. Here's the bottom line. And now, I have liked this Oddity Tech for a long time. I haven't gotten it right, but the stock's big rally earlier this year turned out to be a false start. The good news, though, the fundamentals remain incredible. And the stock's a heck of a lot cheaper than it was six or seven months ago. @ these levels, I think it represents a very compelling value. Doug in Florida. Doug, hi.

Sir Pascal Soria (28:11)

Jim Kramer, longtime viewer.

Jim Cramer (28:14)

I wanted to get your current opinion on Elf Beauty Supply. Okay. You know, someone asked about this last night and they said, what do you think? I'm out there talking a lot of people. I said, you know what? This one's gotten too hard for me. Look, I know I like to wrangleman. I backed him the whole way. But it's just become one of those stocks that's a good tariff. Tariff problem. And the short interest is really big. And right now I think it's slow. But I'm afraid literally that I will get my head blown off. I say this is the level to buy it. Hey, let's stick with, you know, let's stick with Florida. Let's go to Chris in Florida. Chris. Hey, Jimbo. Booyah. How you doing? I am doing well, chief. How about you? Good, very good. Longtime listener, first time caller. Thanks for all you do. Can't be done. My, my question is about the trade desk. Have a small position.

Sir Pascal Soria (29:03)

Want to know if I should buy.

Jim Cramer (29:04)

More, hold or sell. Oh, my God. You know, this is a Jeff Green. And you know, this is maybe one of the top, the worst five stocks in the S&P 500 this year. But you know what? Amazon's in there. I'm not going against Amazon. They're like, they're like, they're like flailing. I don't want to go against them. I really think Jeff's great. But it's just you can't go against the hyperscalers, particularly Amazon, which actually is the largest position we have, my Chapel Trust. Even as I think that at times we clash head to head. Oddity's fundamentals remain incredible. I think at these levels, it represents compelling that much more Man Bunny, including my Susan. With AstraZeneca doubling down on investments in America. I'm hearing why this decision makes sense to the UK's drug makers. Bottom line with the CEO, and it could make sense for you. Then how do you spot a bottom in the market? I'm going to give you my strategy. And of course, oil calls rapid fire. Tonight's edition of the Lighting Mouse. So stay with Kramer. Data centers aren't the only things that companies are spending billions of dollars to build the United States. But President Trump threatening steep tariffs on pharmaceutical imports. The drug makers have announced a ton of manufacturing R and D commitments in this country. Take AstraZeneca. That's the Anglo Swedish pharma giant. In July, AstraZeneca committed to spending $50 billion on US production R&D by 2030. And today, as part of that commitment, the company unveiled a $2 billion investment in Maryland to expand an existing biologics manufacturing facility and build a new state of the art facility for the development and supply of new molecules to be used in clinical trials. Earlier, we had a chance to speak with Sir Pascal Soria. He is the longtime CEO of AstraZeneca about today's news. Check it out. Welcome, Mr. Soria.

Sir Pascal Soria (30:59)

How are you? Jim, good to see you again.

Jim Cramer (31:01)

I am fine. And I'd like to know right now, where are you? Because it looks like you're at a construction site.

Sir Pascal Soria (31:08)

Yes, exactly. I mean, Frederick, we are just announcing a $2 billion investment in Maryland. And the big part of it will come to here, Frederick, where we're building a new biologics manufacturing site. And you see here behind me the final space of this new building. It's a tremendous investment and we are all very excited about it. The second part of the $2 billion will go to a new state of the art clinical manufacturing unit in Gettysburg, Maryland, too.

Jim Cramer (31:40)

Now, one of the things that I know we're all proud of is when we build these great factories, they produce a huge number of jobs. How many people do you think will get employment as you build this facility?

Sir Pascal Soria (31:56)

About 2600 people will get a job. Some of them will be highly skilled scientists and technicians, engineers in the factory and also construction workers. So quite a lot of jobs created over the next five years during the construction period now. And importantly.

Jim Cramer (32:15)

I'm sorry. Go ahead.

Commercial/Advertisement Announcer (32:16)

I'm sorry.

Sir Pascal Soria (32:18)

Yes. Sorry. No, I was just going to say importantly. This is the fourth announcement we make over the last six months in Virginia, in Coppola, Texas, also, we are building a cell therapy plant in, in Maryland. So, you know, it's part of a $50 billion commitment that we have announced we will invest in the US over the next five years in R and D and in manufacturing.

Jim Cramer (32:42)

Now, that $50 billion commitment, which is just huge, also comes with what I regard as being a good deal for your shareholders, too. Involving a deal that's made by our president. Correct?

Sir Pascal Soria (32:54)

Absolutely. And as you probably noticed, our share price over the last year or so has been up 15%. Last time I talked to you was just after the asco, the American Society of Clinical Oncology in Chicago, where we were on the high because we had announced very a great oncology result. So thank you for picking us and thank you for being so insightful recommending us about a year ago.

Jim Cramer (33:21)

Sir, I have to tell you, I've always felt that your stock is undervalued because you have some. You have one of the best cancer portfolios, maybe the best in under you. You pivoted dramatically toward that and go into your strengths, not, I say, making it so that you're in a whole million different baskets. Tell us exactly what your breast cancer portfolio is doing right now, because it does seem like it's maybe among the best, if not the best.

Sir Pascal Soria (33:51)

Yeah, we have a tremendous portfolio in breast cancer. So recently at the esmo, the European Society of Medical Oncology, we presented new data for our products how to in her two positive or her too low breast cancer, which is a substantial number of substantial proportion of breast cancer patients. Tremendous data in early treatment. Also we announced results of that whole way for what is called triple negative breast cancer, which is a terrible disease affecting typically young women. And there's not a lot of great treatment for this disease. And patients pass away very quickly, unfortunately. So really tremendous results. And we demonstrated overall survival benefit. So and we continue building. We have products in clinical development. So we believe that we are going to really make a big impact in breast cancer over the next few years.

Jim Cramer (34:48)

I hope people realize that you're taking on the tough cancers. A lot of people feel like when you hear that someone dies very quickly, it's almost impossible to do the kind of test that is necessary. But your company's put a lot of money at risk to do that. And it has worked out for obviously for the patients, but for shareholders, it's something that most of the drug companies won't do.

Sir Pascal Soria (35:11)

Yeah, this is a great point actually, Jim. And that's something that people often actually underestimate. There's the cost of development in our industry, but also the risk associated. I can tell you we meet as a team twice a month reviewing our new projects and Very often. Most of the time, actually, I signed checks for several hundred million dollars the other day for a new program in breast cancer. I signed for two studies, phase three studies. So a total of $1 billion. And if that fails, of course, it's $1 billion wasted money. So the risk associated with the work we do is very high. But thankfully, we have been very successful. We've had a success rate in the last maybe year, two years of about 80, 90%. So it's been really very successful. And of course, shareholders have appreciated.

Jim Cramer (36:01)

Well, definitely. I mean, actually, for a lot of drug companies, it's been the exact opposite. They have a failure rate of 80%. So this is rather amazing. Now, I want to talk about the most favored nation agreement you reached with the President and why it will actually benefit shareholders. Because a lot of people would say, wait a second, if they have to cut price, they're not going to do well. But it looks to me like a pretty good deal for everybody.

Sir Pascal Soria (36:28)

Yeah, absolutely. I mean, I think we have been able to address the President goals, and I say goals because I believe he had really two goals. The number one goal, of course, was to reduce the cost of medicines for American patients. But his number two goal was to not destroy the industry. America has a leading position in the world in biopharmaceuticals innovation, and it's really important to maintain that lead that the country has globally. So the challenge for everybody in the industry was how do you reduce prices of pharmaceuticals, but at the same time, do not destroy the industry in the process of doing it? And the answer to this was what the President calls equalization or rebalancing. So patients in the US can pay less, but patients in other wealthy countries pay more because there has been a disconnect of prices developing over the last 15 years between the US and Europe, mostly. So this rebalancing will enable us to achieve those goals. And I think. I think, again, shareholders have appreciated the fact that, of course, it will bring a little bit of pain to our financials in the near term, but we can definitely absorb this, but at the same time, provide visibility and certainty over the horizon. And we can now refocus on what we do well, which is innovating for patients.

Jim Cramer (37:51)

Well, it's clear that what you're doing is working because the stock has been among the best that. I follow the last question. You will be changing your listing status soon, in February. What do you think that will do for your visibility in our country?

Sir Pascal Soria (38:07)

Yes, absolutely. You know, we. We have a goal to achieve to reach $80 billion. So revenue by 2030, half of it coming from the United States. 50%. So we're very much a U.S. company. We have 25,000 colleagues in the U.S. we have two large R&D centers, 16 manufacturing sites, more to come. $50 billion commitment in investment. And we wanted to make sure that American investors, large and small and medium sized, could, could buy our shares. ADRs are of course, an option, but they're not a very convenient option for many investors. So we are now listing our shares on the New York Stock Exchange to enable shareholders in the US to actually buy our shares and benefit from the growth this company can deliver in the future. Because we're not only investing in oncology, we are investing in cardiometabolism. Just received receive phase three results of a new drug for hypertension. Fantastic results. In patients who have, who have hypertension, they are on three drugs not controlled. So as you can see, we're investing across a variety of disease areas.

Jim Cramer (39:18)

Well, look, we're thrilled that you're. That you will be changing the listing. I look forward to interviewing you in February when you do that. And congratulations on your incredible success since I've seen you last. It's really rather remarkable. Remarkable. Great job, sir. Really, really great job.

Sir Pascal Soria (39:34)

Thank you, James. Thank you so much.

Jim Cramer (39:36)

That's Sir Pascal Sorio. He's AstraZeneca CEO. And this has been one of the best performing stocks of this era at money's Backyard. Coming up, Kramer takes your calls. And the sky's the limit. It's a fast fire lightning round. Next. Before we get to your calls, guess what? Christmas came early. There's a special offering happening right now to join the CNBC Investing Club. You'll get my top takeaways and every Chapel Trust move. Scan the QR code or go to cnbc.comkramer club. And now it is time to stop for the white round. Christmas. Robert Weitzel himself. Just putting on cars at the time. My steppers Grab a planet sound. And then the lightning round is over. Are you ready, Ski daddy? Time for the light. How about we start with Joe in New Jersey? Joe. Hello, Mr. Kramer. Joe, man, how you been?

Sir Pascal Soria (40:41)

Okay.

Jim Cramer (40:42)

Doing a little bit of fishing, but no life with those stripers. I'm a surf. Oh, thank you, buddy Book waiter. How can I help you? Oh, okay. With Stifle increasing their price target on Mettler Toledo International. Is it a buy down here? You know, this is a very. A very poorly covered company that happens to be a very good company. I always have Felt that people should be focused on it, but they are. They're very not promotional. You got a good one there. All right, let's go to John in New Jersey. John, Jimbo. How you doing today, buddy? Couldn't be better. How about you, dude, if it's not one thing, it's another. Jimbo, you and your book are so hot right now. If they come near you, they'll get third degree burns. Jimbo. Oh, my. Yeah, we have rate cuts on the horizon. We have a housing affordability price versus a short of homes. We, the open army spearheaded by Eric Jackson and Anthony Pomp believe in Canada hasn't been. You want a CEO putting his time and money where it needs to be. I believe this stock will continue to run upwards just like your is running off the shelf. Jimbo, I'm always a gentleman who opens the door. Give me some extra juice on open door technologies. Well, you know what, John? Here's the problem. This stock is high. Given the fact that the company makes no money. I'm not a believer until it makes money. That's just how I am. I love your enthusiasm, but it's not making money. I need to go to Bill in North Carolina. Bill. Oh, yeah, Jim from 336. Appreciate your show and everything that you do. Thank you. Thank you. Still needing to try to learn a lot more. I bought Poet Technologies as a specialist stock. It's losing too much money. It's losing too much money. And we're not. Remember, the era of magical investing is over. So I can't recommend stock. Let's go to Trey in Minnesota. Trey. Hey, Jim. Biohaven stock is down 75% year to date. But the CEO and other insiders exploded $33 million in the last week. You know their migraine success better than anyone. Is now the time to follow the insiders? It was that drug. Okay, well, I'll tell you in full disclosure. I have a deal with Biohaven over a drug that I've invented with the doctor. So I will tell you, the stock seems very low to me. But then again, because I do have that deal, you might just say, well, wait a second. Kramer's. You know, how can you tell? But boy, is it low. And that, ladies and gentlemen, is the conclusion of the lightning round. The lightning round is sponsored by Charles Schwab. Coming up to close out the week, Kramer's helping you make sense of this week's wild market swings and giving you tips on how to make long term money in any market. Next. How did I know we bottom only after we shook off the initial rally this morning, how did I know to tell you to be ready to buy when the time is right like I did last night. If yesterday's brutal session permit me by you just for one day because it's educational universe. It's all about how to spot a bottom. It all starts with something called the S and P oscillator. It's a proprietary measure of buying and selling pressure put out each night after the close the market by a company called Market Edge. Last night at 4:18pm I got the email minus 3.73 on the oscillator. Now the oscillator measures extremes. Zero is equilibrium, tells you nothing, nothing. Plus five means too much exuberance. You got to trim some positions. Plus 1010 means like sell your everything but your core holdings. It's that's rarity though. Same thing on the way down. Minus five is when you have to start buying because we're oversold and due for a rebound. So when I saw it was minus 3.73 close to minus 5 but not there, I knew that whatever bounce we get at the opening would be wrong. Not enough selling pressure. But after the following swoon that I predicted, you get your chance. I've subscribed to this oscillator since 1987, so I've been wrong about half a dozen times. That pretty good record. Now before you leave the office when everything's fresh in your mind like I did last night, I like to go over what are the most important positions. The tells, I call them. The the tells are named after the late great Ricky J. Who taught me how to spot what might be in the other guy's hand. A tell that the person might do. Google he was incredibly special yesterday after everyone thought the only tell was matter was in video right when it turned down, they thought it was the end that was wrong. What actually let us down yesterday were the stocks of Micron and Sandisk to plain vanilla tech storage plays that had been red hot but suddenly turned ice cold. They plummeted and then and only then did in video give up the goals. So I knew to watch the action those two as a prelude to any rally they had the bottom start going up. Next was bitcoin had been in free fall. It needed to find a bottom and then do a U turn or there could be no hope whatsoever. Instead it kept falling and we need to see a combination of soft goods and drug stocks rallying as well as the transports, especially the rails. All aboard. You get that combination? Got a Kind of nice Goldilocks moment. Now here's the tough part. Because we have so much round the clock trading these days. You can't wait for the market to open. But you got to get up real early to see how important the tells are. Trading okay, you set the alarm for 3:15am and first you watch bitcoin. Nothing trades like mad. Overnight. Most important tech stocks and the overnight average, they all trade. Sure enough, when I woke up was real ugly. That was perfect because I could presume that would be at minus 5 when the oscillator was safe to buy. Nvidia was down for bitcoin. Nearly had 80,000. Perfect everything red. That freaks people out and results in what we call a crescendo bottom where everyone throws in the towel at once and then it's time to buy. I came to the office this morning and it was all systems go, real negative, perfect. But then a big shot John Williams, head of the New York Fed, gives this speech where basically says that a rate cut seems like it's inevitability. Market takes off after that because hopes had just been dashed the day before on a strong employment report that we would get a rate cut. Well, that's so good. I knew we were in a jam. No, pretend no. So I said on squawking the street that you couldn't buy this opening. You had to wait for reversal. Not enough to spare, especially when it comes to video. But I knew that once Micron and Sandisk, the two that had let us down yesterday, went lower and then reversed, well, then I knew we'd be home free. That's what led us down yesterday, not in video. The crescendo was happening right in front of me then when in video started printing higher highs and higher lows. After horrendous opening, it was a run for the roses. At that point, the big selling crescendo had been reached. A calm rally began. The action said it all. You have to understand, stocks do speak, they do say things. And if you listen long enough, you can spot a bottom like this coming. You could tell that the rest of the market was okay because the transports led by the truckers in the mighty Union Pacific and the soft goods powered by Johnson Johnson and Procter Gamble took off from the get go, never look back, only to be joined by America's best, which is the best financial tell for positivity. Now next thing you know with the crescendo put in bitcoin rallies from the abyss. And then even in video stock goes higher and you know what? That's all she wrote for the session. Now I know this sounds like hocus pocus, but this is what I did for a living in my hedge fund for years and years and years. I picked bottoms and tops. I even wrote about it in a book called Real Money. So I had the tells, I had the cards, I heard the thunder of the herd and I nailed it. Sounds crazy when I say stocks talk to me, but they do. Maybe after all these years they just like me. I think it's good to have friends in high places. I like to say there's always a bull markets up. I promise everybody. Just for your hero, Matt Money, I'm Jim Papers. See you Monday.

Commercial/Advertisement Announcer (48:36)

All opinions expressed by Jim Cramer on this podcast are solely Kramer's opinions and do not reflect the opinions of cnbc, NBC Universal, or their parent company or affiliates, and may have been previously disseminated by Kramer on television, radio, Internet or another medium. You should not treat any opinion expressed by Jim Cramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Cramer's opinions are based upon information he considers reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Mad Money disclaimer, please visit cnbc.com madmoneydisclaimer. Save over $200 when you book weekly stays with Vrbo this winter. If you haven't seen your college besties since, well, college, you need a week to catch up in a snowy cabin, take a week long vacation and save over $200. Book now@Verbo.com.